Clinical Trials Logo

Filter by:
NCT ID: NCT05786963 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis

Start date: December 29, 2022
Phase:
Study type: Observational

Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.

NCT ID: NCT05786950 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To investigate the relationship among the neural respiratory drive (NRD), the sensation of the dyspnea and the effect of the bronchodilator on each stage COPD patients.

NCT ID: NCT05786872 Recruiting - Clinical trials for Alcohol Use Disorder

Efficacy and Safety of Dual-target DBS for Treatment-resistant Alcohol Use Disorder

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of dual-target deep brain stimulation for treatment-resistant alcohol use disorder.

NCT ID: NCT05786859 Recruiting - Hepatitis B Clinical Trials

The Efficacy and Safety of Rifaximin Treatment

Start date: March 9, 2023
Phase: Early Phase 1
Study type: Interventional

There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure with mild to moderate hepatic encephalopathy will be enrolled in this study according to the inclusion and exclusion criteria, and will be randomly divided into two groups as 1:1.First group is called Rifaximin group, on the basis of comprehensive treatment of liver failure, Rifaximin (Alfa Sigma S.p.A) is added, three times a day, 400 mg each time, for a total of 4 weeks, and observed until 12 weeks after withdrawal. The other group is called standard treatment group (control group), which will receive routine comprehensive treatment for liver failure. The reversal of mild to moderate hepatic encephalopathy in the two groups of patients will be observed within 4 weeks, then follow up to 12 weeks.

NCT ID: NCT05786846 Recruiting - Thyroid Dysfunction Clinical Trials

Serum Thyroid Function After Iodinated Contrast Administration

Start date: February 15, 2023
Phase:
Study type: Observational

This study investigated the changes in serum thyroid function and urinary iodine levels before and after the use of iodinated contrast to analyze the prevalence of thyroid dysfunction in the Chinese euthyroid adults after using iodinated contrast.

NCT ID: NCT05786781 Recruiting - Hemoptysis Clinical Trials

An Exploratory Study on the Application of Transarterial CT Angiography in the Interventional Treatment of Hemoptysis

Start date: March 2, 2023
Phase: N/A
Study type: Interventional

This is a single-arm, exploratory study to evaluate the value of transarterial CT angiography applying Nexaris Angio-CT in the interventional treatment of hemoptysis

NCT ID: NCT05786586 Recruiting - Myopia Clinical Trials

650nm Low-level Red-light for Myopia Control and Prevention in Children

Start date: March 26, 2023
Phase: N/A
Study type: Interventional

A multicenter randomized controlled trial, evaluating the efficacy and safety of 650nm low-level red-light irradiation for myopia control and prevention in children. Participants included children(aged 6 to 12 years, spherical equivalent error of 0.5D or below) who are already myopic at recruitment, and those who are of Emmetropia or low hyperopia.

NCT ID: NCT05786339 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Start date: November 17, 2018
Phase: Phase 1
Study type: Interventional

The bioavailability of Irbesartan (150 mg) developed by Shenzhen Haibin Pharmaceutical Co., Ltd. was compared with that of reference Irbesartan (Aprovel ®,150 mg) produced by Sanofi Clir SNC. The bioequivalence of single dose of test preparation and reference preparation was evaluated in heathy subjects under fasting and fed conditions.

NCT ID: NCT05786313 Recruiting - Clinical trials for Cervical Spinal Cord Injury

Study of Individualized, Precise and Standardized Cervical Open-door Surgery for Cervical Spinal Stenosis

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of individualized, precise and standardized open-door posterior cervical surgery through a single-center, exploratory clinical study, so as to provide a more reliable basis for the treatment of cervical spinal stenosis.

NCT ID: NCT05785949 Recruiting - Cartilage Defects Clinical Trials

Chondro-Gide® Bilayer Collagen Membrane in Knee Cartilage Defect Repair

Start date: April 13, 2023
Phase: N/A
Study type: Interventional

A prospective, multicenter, randomized, parallel controlled study evaluating the safety and efficacy of Chondro-Gide® bilayer collagen membrane in knee cartilage defect repair. The objective of this clinical trial is to evaluate the efficacy and safety of Chondro-Gide® bilayer collagen membrane in knee cartilage defect repair